Next Article in Journal
Analysis and Functional Verification of PlPM19L Gene Associated with Drought-Resistance in Paeonia lactiflora Pall.
Next Article in Special Issue
Validation of Six Commercial Antibodies for the Detection of Heterologous and Endogenous TRPM8 Ion Channel Expression
Previous Article in Journal
Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma
Previous Article in Special Issue
TRPV3 and Itch: The Role of TRPV3 in Chronic Pruritus according to Clinical and Experimental Evidence
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 24
10.3390/ijms232415692
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Changes in TRPV1 Expression as Well as Substance P and Vasoactive Intestinal Peptide Levels Are Associated with Recurrence of Pterygium

by
Hatice Deniz İlhan
1,
Betül Ünal
2,
Yusuf Ayaz
1 and
Nuray Erin
3,*
1
Department of Ophthalmology, Faculty of Medicine, Akdeniz University, Antalya 07070, Turkey
2
Department of Pathology, Faculty of Medicine, Akdeniz University, Antalya 07070, Turkey
3
Department of Medical Pharmacology, Faculty of Medicine, Akdeniz University, Antalya 07070, Turkey
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(24), 15692; https://doi.org/10.3390/ijms232415692
Submission received: 18 November 2022 / Revised: 6 December 2022 / Accepted: 7 December 2022 / Published: 10 December 2022
(This article belongs to the Special Issue Targeting TRP Channels for Pain, Itch and Inflammation Relief)
Browse Figures
Review Reports Versions Notes

Abstract

:
Pterygium, a disease of the ocular surface, is characterized by the proliferation and invasion of fibrovascular tissue. Chronic inflammation contributes to pterygium occurrence. Sensory neuropeptides of TRPV1-positive nerve fibers are involved in inflammation and corneal wound healing. The possible association between TRPV1 in nerve fibers and neuropeptides such as Substance P (SP) and Vasoactive Intestinal Peptide (VIP) in the recurrence of pterygium has not been examined before. The pterygia from 64 patients were used to determine changes in SP and VIP levels using 10 min acetic-acid extraction that yielded mainly neuronal peptides. There was a sufficient amount of pterygium tissues from the 35 patients for further immunohistochemical analysis of TRPV1 and S100, which is a glial marker to visualize nerve fibers. SP and VIP levels increased markedly in cases with primary and secondary recurrences, and there was a close correlation between SP and VIP levels. TRPV1 expression increased in the epithelium, while stromal expression decreased in recurrences. Nerve fibers were demonstrated mainly in the stroma, and serial sections confirmed the localization of TRPV1 with the nerve fibers. These results together with previous findings demonstrated that the increased epithelial expression of TRPV1 in recurrent pterygia might be involved in the pathogenesis, and the inhibition of epithelial TRPV1 activity may prevent recurrence.

1. Introduction

Pterygium is a disease of the ocular surface that is characterized by the proliferation and invasion of fibrovascular tissue from the bulbar conjunctiva to the cornea. Chronic inflammation may contribute to pterygium occurrence. It was postulated that inflammation at the junction of the conjunctival blood vessels and Bowman’s membrane, which attracts conjunctival blood vessels on the cornea, may cause pterygium [1]. Specifically, inflammation induced by ultraviolet B (UV-B) radiation may contribute to the pathogenesis of pterygium [2]. In accordance, levels of inflammatory cytokines such as IL-6, IL-8 and tumor necrosis factor-α (TNF- α) are increased in pterygium [3,4,5].
Surgical removal is necessary for the treatment of pterygium in the event of ocular surface changes. Recurrence is the main postoperative problem, which can be seen in up to 80% of patients [6]. Prediction of the factors affecting recurrence is not fully understood. Pterygium follows the radial extensions of the corneal nerves; hence, nerve fibers may play an important role in its development and, perhaps, in recurrence [7,8,9]. However, to our knowledge, innervation of the pterygium has not been studied before.
TRPV1, a receptor for capsaicin, is found in peptidergic sensory nerve fibers. TRPV1-positive sensory nerve fibers are involved in local inflammatory response via the release of neuropeptides, such as Substance P (SP) [10]. Sensory neuropeptides of TRPV1-positive nerve fibers play a role in inflammation and corneal wound healing [11,12,13,14]. Specifically, SP is a potent chemoattractant for fibroblasts and vascular endothelial cells, such that SP might be involved in the profibrogenic and angiogenic mechanisms of pterygium tissue [9]. However, only a few studies have examined the possible changes in SP levels in pterygium in relation to recurrence [15].
Vasoactive intestinal peptide (VIP) is another neuropeptide that may modulate inflammatory responses in the eye. VIP is found in the glands around the eyelid and ocular surface [16]. In addition, VIP accelerates endothelial wound closure of the cornea [17]. VIP is co-localized with SP in rat episclera [18], and VIP-immunoreactive nerve fibers are in close contact with substance P immunoreactive fibers in the skin of human faces [19].
TRPV1 expression has been shown in pterygium tissue [20]. However, the possible role of TRPV1, nerve fibers and neuropeptides in the recurrence of pterygium has not been examined before. Hence, in the present study, we aimed to examine the possible relationship between SP, VIP and TRPV1 in cases with a recurrence of pterygium.

2. Results

The study included 39 males and 25 females with average ages of 51.5 (min: 27, max: 71) and 57.6 (min: 31, max: 75). Eleven of forty-four primary cases experienced recurrence within 24 months (3–24 months). Pterygium recurred in six of the relapse cases. All of those who had recurrent surgery had at least one and at most six pterygium surgeries. The minimum follow-up period for patients was 24 months. The cases included in the study were divided into the following three groups: a primary group (group 1), recurrence of primary group (group 2) and a group that had recurrence surgery (group 3). The demographic features of these groups can be seen in Table 1.

2.1. Changes in SP and VIP Levels

As seen in Table 2, the SP and VIP levels of pterygium tissue in the primary group who did not have a recurrence in the follow-up period (group 1) were markedly lower compared to the primary pterygia of patients who had recurrence (group 2). Similarly, SP as well as VIP levels of patients with multiple recurrences (at least one recurrence at the time of surgery, group 3) were markedly higher compared to group 1. We also analyzed the data based on the number of recurrences and the time between the last two recurrences (Table 3). Patients who had recurrence within 6 months had significantly higher levels of SP compared to patients with recurrence after 6 months.
A close correlation between SP and VIP levels was observed in all three groups as determined by linear regression. The Pearson correlation coefficient (r) was more than 0.9. Specifically, r-values were 0.97; 0.98; 0.92 for group 1, group 2, and group 3, respectively (Figure 1).

2.2. Changes in TRPV1 Expression

Diffuse TRPV1 expression was observed in the pterygium. As seen in Figure 2, both the epithelium and the stroma were positively stained.

2.3. TRPV1 Expression in Epithelium and Stroma (Table 4)

Diffuse but low-intensity staining was observed in half of the primary pterygia cases such that more than 50% of cells were TRPV1 positive (9 out of 18 cases, group 1). Staining intensity was high only in three cases (3/18). Epithelial staining was not observed in one case.
Table
Table 4. Expression. Distribution and Intensity of TRPV1 and S100 in Group 1, 2, 3. * p = 0.035 compared to group 1 epithelium. ** p = 0.0095 compared to group 1 stroma. 3–4+ represents distribution area of 50% and more. 2–3+ represents distribution area of 5–15% for S100 staining.
Table 4. Expression. Distribution and Intensity of TRPV1 and S100 in Group 1, 2, 3. * p = 0.035 compared to group 1 epithelium. ** p = 0.0095 compared to group 1 stroma. 3–4+ represents distribution area of 50% and more. 2–3+ represents distribution area of 5–15% for S100 staining.
3–4+ TRPV1 DistributionTRPV1 IntensityS100 Distribution (2–3+)
Group 1Epithelium9/183/18
Stroma6/1810/18 *12/18 (67%)
Group 2Epithelium4/81/8
Stroma1/80/8 **5/8 (62.5%)
Group 3Epithelium4/90/9
Stroma1/93/94/9 (44%)
In group 2 (primary pterygia which reoccurred within 24 months), TRPV1 were positively stained in the epithelium in all cases (n = 8), and more than 50% of cells were TRPV1 positive in half of the cases (4 of 8 cases).
In group 3 (pterygium of multiple reoccurrences), TRPV1 was positively stained in the epithelium in all cases (n = 9), and more than 50% of cells were TRPV1 positive in four of nine cases. Staining intensity was low to moderate in all groups.

2.4. TRPV1 Expression in Stroma (Table 4)

Group 1. Stromal staining was observed in all samples. Over 50 % of cells were TRPV1 positive in six out of eighteen primary pterygia cases. Intense staining (3+) was observed in 10 out of 18 cases. The intensity of stromal staining was significantly higher than that of the epithelium when a staining intensity of 3+ was compared within this group (Fisher’s exact test).
Group 2. Stromal staining was observed in all of the samples except one. Over 50% of cells were TRPV1 positive in one out of eight cases. Intense staining (3+) was not observed in any case, and intensity was mostly moderate. The area of staining was markedly greater in the epithelium compared to the stroma in this group when staining areas of 75–100% (grade 4) were compared (3/8 vs. 0/8) (Fisher’s exact test). (In Table 4, grade 3 and 4 are shown for distribution). Interestingly, the staining intensity of the stroma (3+) was markedly lower in group 2 compared to group 1.
Group 3. Stromal staining was observed in all samples except one. Staining over 50% was found in one out of nine cases. Intense stromal staining (3+) was observed in three out of nine cases. Staining intensity and the area of staining were not significantly different among the epithelium and the stroma in this group.

2.5. S100 Immunoreactivity

S100 is the marker for glial cells and was used to visualize nerve fibers (Raponi, E., 2007). Intense punctuate staining was observed in all groups, and the area of S100 staining was similar among groups (Table 4) (Figure 3). The immunoreactivity score for S100 was 1.94+/−0.19, 1.75+/−0.31,1.67+/−0.37 for groups 1, 2 and 3, respectively, demonstrating that nerve fibers constitute, on average, 5–10 % of the stromal area. S100 staining was performed in sections of the tissues to determine possible co-localization of TRPV1 with S100. As seen in Figure 3, TRPV1 immunoreactivity was present in areas of S100 positivity.

3. Discussion

We have demonstrated for the first time that both SP and VIP levels increased markedly in cases with primary and secondary recurrences (groups 2 and 3, respectively) and that there was a close correlation between SP and VIP levels. TRPV1 expression increased in the epithelium, while stromal expression decreased in primary recurrences (group 2) compared to non-recurrent cases (group 1). In addition, TRPV1 immunoreactivity was stronger in the stroma compared to the epithelium of non-recurrent cases. Nerve fibers were demonstrated mainly in the stroma, and serial sections confirmed the localization of TRPV1 with the nerve fibers. Changes in the stroma and epithelial expression of TRPV1 in group 3 were somewhat similar to group 2, but the differences were not statistically significant. These variations might be due to the presence of previous surgery for pterygium/pterygia, such that post-surgical changes may have altered the structure of newly formed pterygium. Specifically, it was shown that corneal subbasal nerve fibers deteriorated in pterygium patients, and pterygium excision improved corneal sensitivity and increased corneal subbasal nerve density [21].
TRPV channels that are sensitive to heat are present in conjunctival epithelial and endothelial cells, and TRPV1, TRPV2 and TRPV3 activities are considered essential homeostatic mechanisms for corneal endothelial function under different ambient conditions [22,23]. In human corneal endothelial cells, capsaicin, a selective TRPV1 agonist, induces Ca2+ transients [23]. Furthermore, the exposure of human corneal epithelial cells to hypertonic stress elicits TRPV1 activation, leading to increases in pro-inflammatory cytokine release via mitogen-activated protein kinase and NF-κB signaling [24]. Inflammation is considered an important factor in the occurrence and recurrence of pterygium [3,4,5,25,26]. There are a few reports about the expression of TRPV1 in pterygium. It was shown that there is a significant correlation between TRPV1 and TRPV3 expression in pterygium; this, however, is not associated with recurrence [20]. It was also shown that 90% of TRPV1 immunoreactivity is localized in the epithelial layers of pterygia in a small group of both primer and recurrence cases [20]. Garreis et al. also demonstrated a similar pattern of TRPV1 staining in pterygia as well as expression in human pterygial epithelial cells. In addition, they have documented that TRPV1 may mediate the mitogenic effects of growth factors and suggested that TRPV1 might be a potential therapeutic candidate in pterygium [27]. Our findings are somewhat in agreement with these findings and further document a shift from stromal staining towards the epithelium in recurrent pterygium. Specifically, we observed an increase in TRPV1 in the epithelial layer in cases with recurrence, while the opposite occurred for stromal expression. Our findings, together with previous findings, suggest that inhibition of epithelial TRPV1 may inhibit the growth of pterygium.
TRPV1 is expressed in both neuronal and non-neuronal cells. It was shown that TRPV1+ nerves account for ~40% of nerve fiber length in the intact corneal epithelium and ~80% in the stroma and that following injury, TRPV1+ nerve density increases in a mouse model [28]. The activation of TRPV1+ nerves in the eye induces the release of neuropeptides such as neurokinins, calcitonin gene-related peptide (CGRP), and substance P (SP) [29]. In accordance, we observed a significant innervation of the stroma of pterygium with nerve fibers in all groups. In addition, short acetic acid extraction of neuronal peptides [30] yielded a significant amount of SP and VIP, which was markedly increased in recurrent pterygia. Given the fact that patients in group 2 (primary recurrence) did not have previous surgery, these changes are directly related to the recurrence capacity of the pterygium. It was previously shown that expression of the NK1 receptor, the receptor for SP, is increased in pterygia, and SP induces cell migration in pterygium fibroblasts which is inhibited by an NK(1) receptor antagonist [9]. Hence, it was postulated that SP contributes to the shape of the lesion through its profibrogenic and angiogenic actions. Specifically, NK-1 antagonists reduced both corneal hemangiogenesis and lymphangiogenesis in two mouse models of corneal neovascularization [31]. Our results verify to some extent and further demonstrate that SP might be involved in recurrence. The density of nerve fibers was not markedly different among groups, hence increased neuronal peptide levels are likely to be due to the sensitization of these nerve fibers. Therefore, identification of the factors that lead to these changes is required to find effective preventive measures. Along these lines, TRPV1 modulators might be effective in decreasing neuropeptide contents, consequent inflammation and recurrence.
SP has a dual function such that while it has profibrogenic and angiogenic actions, a lack of SP or inhibition of SP activity may lead to different pathological changes in the eye. SP participates in the early phase of wound healing [32], and a lack of SP promotes neurotrophic keratitis [33,34]. Similarly, SP promotes wound healing in the diabetic cornea and induces nerve fiber regeneration to restore corneal sensitivity. On the other hand, blocking SP activity results in pathological diabetic epithelial changes and reduced corneal sensitivity in mice [35,36]. Hence, the modulation of SP activity rather than complete inhibition might be a better approach for proliferative eye pathologies.
Studies suggest important regulatory roles for VIP in the eye. Specifically, nerve fibers in the human lacrimal gland interstice mainly express VIP [16,37]. VIP+ fibers are also present close to the acini of human meibomian glands [38]. VIP is present along the epithelial–stromal junction and adjacent to goblet cells, and stimulates mucin secretion by conjunctival goblet cells [39]. Similarly, VIP is involved in smooth muscle relaxation and the excretion of secretions in the intestinal system [40]. VIP also has important anti-inflammatory and anti-viral effects [40,41,42]. Hence, the increased levels of VIP observed here might be a protective mechanism for the increased inflammation observed in pterygia.
Our findings demonstrate that VIP levels are increased in recurrent pterygium, and the levels closely correlate with SP levels. Given the fact that TRPV1 expression is co-localized with the majority of stromal nerve fibers and the close correlation among SP and VIP levels, it is likely that both of these peptides are present in TRPV1+ sensory nerve fibers. Similarly, co-localization was demonstrated in rat episclera [18]. VIP-immunoreactive nerve fibers are in close contact with substance P immunoreactive fibers in skin biopsies of the human face [19]. Hence, the inhibition of TRPV1+ sensory nerve fibers may lead to a sustained decrease in VIP, which may have detrimental consequences. Similarly, it was shown that TRPV1 inhibition augments inflammation and N-Oleoyl dopamine, a TRPV1 agonist, has strong anti-inflammatory actions [43,44]. These aspects should be further evaluated given the fact that TRPV1 antagonists are in clinical trials. Specifically, Tivanisiran (SYL1001) is a small interfering RNA (siRNA) targeting TRPV1, administered in solution as eye drops and is currently in phase 3 clinical research for Dry Eye Disease treatment (NCT05310422). Although the short-term use of Tivanisiran was found to be safe, long-term use should be evaluated in more detail.
In conclusion, our results, together with previous findings, suggest that the increased epithelial expression of TRPV1 found in recurrent pterygia is likely to be involved in pathogenesis, and inhibition of epithelial TRPV1 activity may prevent recurrence. On the other hand, complete inhibition of the TRPV1+ stromal nerve fibers in pterygium may hinder the protective effects of neuropeptides such as VIP. Furthermore, SP also has dual functions such that it induces inflammation but also enhances wound healing and is part of a defense system involving corneal protection. Hence, the modulation of SP and neuronal TRPV1 activity rather than complete inhibition seems to be required for the prevention of pterygium as well as for safety.

4. Materials and Methods

The local ethics committee approved this randomized prospective study (Approval Number 3005.2018/392). The study was carried out in compliance with ethical standards, and informed consent was obtained from all patients who participated in this study. Pterygium samples taken from patients who were operated on at the Akdeniz University Ophthalmology Department were used. Exclusion criteria were autoimmune diseases affecting the ocular surface (e.g., Sjögren, rheumatoid arthritis), diabetes, uveitis, scleritis, those who had ophthalmic surgery or ocular trauma other than pterygium surgery, facial paralysis, glaucoma, as well as patients receiving steroids and non-steroid anti-inflammatory drugs. The cases were evaluated in terms of the morphology of the pterygium using the grade defined by Tan et al. [25]. All cases were grade 3, whether primary or recurrent, with a vertical length extending more than 3 mm from the limbus to the center of the cornea. Samples of forty-four primary and twenty recurrent cases with at least 24 months of postoperative follow-up were included in the study.
An experienced surgeon (HDI) performed all surgeries, and the procedure was pterygium surgery with conjunctival autograft in all patients. The excised pterygium tissue was divided into two parts. One part was transported in liquid nitrogen to the laboratory and stored at −80 °C. The remaining part was sent for pathological examination in formaldehyde.

4.1. Measurement of SP and VIP Levels

Tissues from 64 patients stored at −80 °C were weighed with a precision scale. Each tissue was collected in 1.5 mL tubes, phosphate-buffered saline was added, and the washing procedure was performed with centrifugation at 9000 rpm for 4 min. After PBS was discarded, 2% acetic acid was added, and extractions were obtained by performing incubation at 95 °C for 10 min, as described before [30]. Peptide levels obtained within 10 min of acetic acid incubation were mainly derived from neuronal tissue, as demonstrated before for SP levels [45]. VIP levels were measured using a Human VIP ELISA Kit (Elabscience cat. no.: E-EL-H2155, TX, USA), and SP levels were measured using an EIA kit (Cayman, cat. no.:583751, MI, USA) according to the manufacturer’s instructions. From each sample, 25 and 50 μL were used for the immunoassay of peptides, which provided results that were within the confidence interval (95%).

4.2. Histopathological Evaluation

There was a sufficient amount of pterygium tissues from the 35 patients for further immunohistochemical (IHC) analysis of TRPV1 and S100. For IHC staining, samples were prepared on a positively charged slide with a tissue thickness of 4 μm. The tissue preparations were partially deparaffinized. In accordance with the protocol, the samples were stained using a mouse monoclonal anti-S100 (Thermo Scientific (Clone 4C4.9; 1:100), Waltham, MA, USA) and a rabbit polyclonal TRPV1 antibody (Novus Biologicals (NBP171774; dilution, 1:100), Littleton, CO, USA). In order to determine possible co-localization, consequent sections were stained with TRPV1 and S100. An experienced pathologist conducted the analysis blindly under a light microscope.
The epithelium, connective tissue, and the area of nerve fibers were evaluated separately for TRPV1 staining. Because TRPV1 positivity was more diffuse, a four-stage immunoreactivity scale was used to evaluate the localization (grade 0, no stained cells; grade 1, <25%; grade 2, 25–50%; grade 3, >50–75%; and grade 4, >75%). Staining intensity was graded as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. S100 staining was used to determine neuronal innervation of the pterygium. Nerve fibers were scarce but were strongly stained; hence, the staining intensity was 3 in all samples. To obtain an immunoreactivity score, the percentage of stained cells in this group was graded differently, as follows: grade 0, no stained cells; grade 1, <5%; grade 2, 5–10%; grade 3, >10–15%. The immune reactivity score was calculated by multiplying the immune reactivity scale by the percentage. A statistical analysis was performed using both intensity and distribution values separately as well as immune reactivity scores.

4.3. Statistical Analysis

A statistical analysis was performed using the GraphPad InStat program (CA, USA). Data were analyzed using the chi-square test for categorical variables, or the t-test for independent variables. A p-value of less than 0.05 was considered statistically significant. Correlation analyses were performed by calculating Pearson’s correlation coefficient.

Author Contributions

Conceptualization, N.E. and H.D.İ.; methodology, N.E. and H.D.İ.; analysis of the pathological samples, B.Ü.; formal analysis, N.E. and H.D.İ.; data curation, N.E., H.D.İ. and Y.A.; writing N.E. and H.D.İ.; review and editing, N.E. and H.D.İ. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Akdeniz University Research Unit [project no: TSA-2020-4981].

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Akdeniz University (Approval Number: 3005.2018/392).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Acknowledgments

We would like to thank Özlem Akdeniz for her technical help during peptide extraction and consequent ELISAs of SP and VIP.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Wong, W.W. A hypothesis on the pathogenesis of pterygiums. Ann. Ophthalmol. 1978, 10, 303–308. [Google Scholar] [PubMed]
  2. Chui, J.; Di Girolamo, N.; Wakefield, D.; Coroneo, M.T. The pathogenesis of pterygium: Current concepts and their therapeutic implications. Ocul. Surf. 2008, 6, 24–43. [Google Scholar] [CrossRef] [PubMed]
  3. Kria, L.; Ohira, A.; Amemiya, T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem. 1996, 98, 195–201. [Google Scholar] [CrossRef] [PubMed]
  4. Kria, L.; Ohira, A.; Amemiya, T. Growth factors in cultured pterygium fibroblasts: Immunohistochemical and ELISA analysis. Graefes Arch. Clin. Exp. Ophthalmol. 1998, 236, 702–708. [Google Scholar] [CrossRef] [PubMed]
  5. Di Girolamo, N.; Kumar, R.K.; Coroneo, M.T.; Wakefield, D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Investig. Ophthalmol. Vis. Sci. 2002, 43, 3430–3437. [Google Scholar]
  6. Fernandes, M.; Sangwan, V.S.; Bansal, A.K.; Gangopadhyay, N.; Sridhar, M.S.; Garg, P.; Aasuri, M.K.; Nutheti, R.; Rao, G.N. Outcome of pterygium surgery: Analysis over 14 years. Eye 2005, 19, 1182–1190. [Google Scholar] [CrossRef] [Green Version]
  7. Muller, L.J.; Marfurt, C.F.; Kruse, F.; Tervo, T.M. Corneal nerves: Structure, contents and function. Exp. Eye Res. 2003, 76, 521–542. [Google Scholar] [CrossRef]
  8. Auran, J.D.; Koester, C.J.; Kleiman, N.J.; Rapaport, R.; Bomann, J.S.; Wirotsko, B.M.; Florakis, G.J.; Koniarek, J.P. Scanning slit confocal microscopic observation of cell morphology and movement within the normal human anterior cornea. Ophthalmology 1995, 102, 33–41. [Google Scholar] [CrossRef]
  9. Chui, J.; Di Girolamo, N.; Coroneo, M.T.; Wakefield, D. The role of substance P in the pathogenesis of pterygia. Investig. Ophthalmol. Vis. Sci. 2007, 48, 4482–4489. [Google Scholar] [CrossRef] [Green Version]
  10. Fischer, M.J.M.; Ciotu, C.I.; Szallasi, A. The Mysteries of Capsaicin-Sensitive Afferents. Front. Physiol. 2020, 11, 554195. [Google Scholar] [CrossRef]
  11. Gallar, J.; Pozo, M.A.; Rebollo, I.; Belmonte, C. Effects of capsaicin on corneal wound healing. Investig. Ophthalmol. Vis. Sci. 1990, 31, 1968–1974. [Google Scholar]
  12. Araki, K.; Ohashi, Y.; Kinoshita, S.; Hayashi, K.; Kuwayama, Y.; Tano, Y. Epithelial wound healing in the denervated cornea. Curr. Eye Res. 1994, 13, 203–211. [Google Scholar] [CrossRef]
  13. Garcia-Hirschfeld, J.; Lopez-Briones, L.G.; Belmonte, C. Neurotrophic influences on corneal epithelial cells. Exp. Eye Res. 1994, 59, 597–605. [Google Scholar] [CrossRef] [PubMed]
  14. Mikulec, A.A.; Tanelian, D.L. CGRP increases the rate of corneal re-epithelialization in an in vitro whole mount preparation. J. Ocul. Pharmacol. Ther. 1996, 12, 417–423. [Google Scholar] [CrossRef] [PubMed]
  15. Murphy, C.J.; Marfurt, C.F.; McDermott, A.; Bentley, E.; Abrams, G.A.; Reid, T.W.; Campbell, S. Spontaneous chronic corneal epithelial defects (SCCED) in dogs: Clinical features, innervation, and effect of topical SP, with or without IGF-1. Investig. Ophthalmol. Vis. Sci. 2001, 42, 2252–2261. [Google Scholar]
  16. Seifert, P.; Stuppi, S.; Spitznas, M.; Weihe, E. Differential distribution of neuronal markers and neuropeptides in the human lacrimal gland. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234, 232–240. [Google Scholar] [CrossRef]
  17. Satitpitakul, V.; Sun, Z.; Suri, K.; Amouzegar, A.; Katikireddy, K.R.; Jurkunas, U.V.; Kheirkhah, A.; Dana, R. Vasoactive Intestinal Peptide Promotes Corneal Allograft Survival. Am. J. Pathol. 2018, 188, 2016–2024. [Google Scholar] [CrossRef] [Green Version]
  18. Ladek, A.M.; Trost, A.; Bruckner, D.; Schroedl, F.; Kaser-Eichberger, A.; Lenzhofer, M.; Reitsamer, H.A.; Strohmaier, C.A. Immunohistochemical Characterization of Neurotransmitters in the Episcleral Circulation in Rats. Investig. Ophthalmol. Vis. Sci. 2019, 60, 3215–3220. [Google Scholar] [CrossRef] [Green Version]
  19. Nolano, M.; Provitera, V.; Caporaso, G.; Stancanelli, A.; Leandri, M.; Biasiotta, A.; Cruccu, G.; Santoro, L.; Truini, A. Cutaneous innervation of the human face as assessed by skin biopsy. J. Anat. 2013, 222, 161–169. [Google Scholar] [CrossRef]
  20. Assimakopoulou, M.; Pagoulatos, D.; Nterma, P.; Pharmakakis, N. Immunolocalization of cannabinoid receptor type 1 and CB2 cannabinoid receptors, and transient receptor potential vanilloid channels in pterygium. Mol. Med. Rep. 2017, 16, 5285–5293. [Google Scholar] [CrossRef] [Green Version]
  21. Zhao, Z.; Zhang, J.; Liang, H.; Zhang, S.; Shao, C.; Fan, X.; Fu, Y. Corneal Reinnervation and Sensitivity Recovery after Pterygium Excision. J. Ophthalmol. 2020, 2020, 1349072. [Google Scholar] [CrossRef]
  22. Mergler, S.; Valtink, M.; Coulson-Thomas, V.J.; Lindemann, D.; Reinach, P.S.; Engelmann, K.; Pleyer, U. TRPV channels mediate temperature-sensing in human corneal endothelial cells. Exp. Eye Res. 2010, 90, 758–770. [Google Scholar] [CrossRef] [PubMed]
  23. Mergler, S.; Garreis, F.; Sahlmuller, M.; Reinach, P.S.; Paulsen, F.; Pleyer, U. Thermosensitive transient receptor potential channels in human corneal epithelial cells. J. Cell Physiol. 2011, 226, 1828–1842. [Google Scholar] [CrossRef] [PubMed]
  24. Pan, Z.; Wang, Z.; Yang, H.; Zhang, F.; Reinach, P.S. TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells. Investig. Ophthalmol. Vis. Sci. 2011, 52, 485–493. [Google Scholar] [CrossRef] [Green Version]
  25. Tan, D.T.; Chee, S.P.; Dear, K.B.; Lim, A.S. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch. Ophthalmol. 1997, 115, 1235–1240. [Google Scholar] [CrossRef]
  26. Tan, J.; Vollmer-Conna, U.; Tat, L.; Coroneo, M. Dry-Eye Disease in Recurrent Pterygium. Ophthalmic. Res. 2019, 61, 199–203. [Google Scholar] [CrossRef]
  27. Garreis, F.; Schroder, A.; Reinach, P.S.; Zoll, S.; Khajavi, N.; Dhandapani, P.; Lucius, A.; Pleyer, U.; Paulsen, F.; Mergler, S. Upregulation of Transient Receptor Potential Vanilloid Type-1 Channel Activity and Ca2+ Influx Dysfunction in Human Pterygial Cells. Investig. Ophthalmol. Vis. Sci. 2016, 57, 2564–2577. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Jiao, H.; Ivanusic, J.J.; McMenamin, P.G.; Chinnery, H.R. Distribution of Corneal TRPV1 and Its Association With Immune Cells During Homeostasis and Injury. Investig. Ophthalmol. Vis. Sci. 2021, 62, 6. [Google Scholar] [CrossRef] [PubMed]
  29. Belmonte, C.; Aracil, A.; Acosta, M.C.; Luna, C.; Gallar, J. Nerves and sensations from the eye surface. Ocul. Surf. 2004, 2, 248–253. [Google Scholar] [CrossRef] [PubMed]
  30. Erin, N.; Clawson, G.A. Parameters affecting substance P measurement in heart, lung, and skin. Biotechniques 2004, 37, 232–239. [Google Scholar] [CrossRef]
  31. Bignami, F.; Giacomini, C.; Lorusso, A.; Aramini, A.; Rama, P.; Ferrari, G. NK1 receptor antagonists as a new treatment for corneal neovascularization. Investig. Ophthalmol. Vis. Sci. 2014, 55, 6783–6794. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Hong, H.S.; Lee, J.; Lee, E.; Kwon, Y.S.; Lee, E.; Ahn, W.; Jiang, M.H.; Kim, J.C.; Son, Y. A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat. Med. 2009, 15, 425–435. [Google Scholar] [CrossRef] [PubMed]
  33. Araki-Sasaki, K.; Aizawa, S.; Hiramoto, M.; Nakamura, M.; Iwase, O.; Nakata, K.; Sasaki, Y.; Mano, T.; Handa, H.; Tano, Y. Substance P-induced cadherin expression and its signal transduction in a cloned human corneal epithelial cell line. J. Cell Physiol. 2000, 182, 189–195. [Google Scholar] [CrossRef]
  34. Nishida, T.; Inui, M.; Nomizu, M. Peptide therapies for ocular surface disturbances based on fibronectin-integrin interactions. Prog. Retin. Eye Res. 2015, 47, 38–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Yang, L.; Di, G.; Qi, X.; Qu, M.; Wang, Y.; Duan, H.; Danielson, P.; Xie, L.; Zhou, Q. Substance P promotes diabetic corneal epithelial wound healing through molecular mechanisms mediated via the neurokinin-1 receptor. Diabetes 2014, 63, 4262–4274. [Google Scholar] [CrossRef] [Green Version]
  36. Nakamura, M.; Ofuji, K.; Chikama, T.; Nishida, T. The NK1 receptor and its participation in the synergistic enhancement of corneal epithelial migration by substance P and insulin-like growth factor-1. Br. J. Pharmacol. 1997, 120, 547–552. [Google Scholar] [CrossRef] [Green Version]
  37. Seifert, P.; Spitznas, M. Vasoactive intestinal polypeptide (VIP) innervation of the human eyelid glands. Exp. Eye Res. 1999, 68, 685–692. [Google Scholar] [CrossRef]
  38. Cox, S.M.; Nichols, J.J. The neurobiology of the meibomian glands. Ocul. Surf. 2014, 12, 167–177. [Google Scholar] [CrossRef]
  39. Diebold, Y.; Rios, J.D.; Hodges, R.R.; Rawe, I.; Dartt, D.A. Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Investig. Ophthalmol. Vis. Sci. 2001, 42, 2270–2282. [Google Scholar]
  40. Villanueva-Romero, R.; Gutierrez-Canas, I.; Carrion, M.; Perez-Garcia, S.; Seoane, I.V.; Martinez, C.; Gomariz, R.P.; Juarranz, Y. The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis. J. Immunol. Res. 2018, 2018, 6043710. [Google Scholar] [CrossRef]
  41. He, Y.; Zang, N.; Liu, E.M. Vasoactive intestinal peptide: A potential target for antiviral therapy. Sheng Li Xue Bao 2022, 74, 419–433. [Google Scholar] [PubMed]
  42. Jansen, M.I.; Thomas Broome, S.; Castorina, A. Exploring the Pro-Phagocytic and Anti-Inflammatory Functions of PACAP and VIP in Microglia: Implications for Multiple Sclerosis. Int. J. Mol. Sci. 2022, 23, 4788. [Google Scholar] [CrossRef] [PubMed]
  43. Wilhelmsen, K.; Khakpour, S.; Tran, A.; Sheehan, K.; Schumacher, M.; Xu, F.; Hellman, J. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. J. Biol. Chem. 2014, 289, 13079–13100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Joffre, J.; Wong, E.; Lawton, S.; Lloyd, E.; Nguyen, N.; Xu, F.; Sempio, C.; Kobzik, L.; Zlatanova, I.; Schumacher, M.; et al. N-Oleoyl dopamine induces IL-10 via central nervous system TRPV1 and improves endotoxemia and sepsis outcomes. J. Neuroinflammation 2022, 19, 118. [Google Scholar] [CrossRef]
  45. Erin, N.; Ulusoy, O. Differentiation of neuronal from non-neuronal Substance P. Regul. Pept. 2009, 152, 108–113. [Google Scholar] [CrossRef]
Ijms 23 15692 g001 550
Figure 1. Correlation between SP and VIP levels in primary group (group 1) with no recurrence, recurrence of primary group (group 2) and group that had recurrence surgery (group 3). r shows Pearson correlation coefficient. Close correlation is seen in all groups.
Figure 1. Correlation between SP and VIP levels in primary group (group 1) with no recurrence, recurrence of primary group (group 2) and group that had recurrence surgery (group 3). r shows Pearson correlation coefficient. Close correlation is seen in all groups.
Ijms 23 15692 g001
Ijms 23 15692 g002 550
Figure 2. Immunohistochemical analysis of TRPV1 in pterygia. Representative figure of diffuse and intense staining of epithelium is seen in Panel (A) (*). Intense staining of stroma (*) is seen in Panel (B) at 200 magnification.
Figure 2. Immunohistochemical analysis of TRPV1 in pterygia. Representative figure of diffuse and intense staining of epithelium is seen in Panel (A) (*). Intense staining of stroma (*) is seen in Panel (B) at 200 magnification.
Ijms 23 15692 g002
Ijms 23 15692 g003 550
Figure 3. S100 and TRPV1 staining in consequent sections. Panel (A,C): appearance at 200 magnification. Panel (B,D): appearance of demarcated areas at 400 magnification. TRPV1 staining is diffuse and covers the areas of S100 immunoreactivity.
Figure 3. S100 and TRPV1 staining in consequent sections. Panel (A,C): appearance at 200 magnification. Panel (B,D): appearance of demarcated areas at 400 magnification. TRPV1 staining is diffuse and covers the areas of S100 immunoreactivity.
Ijms 23 15692 g003
Table
Table 1. Demographic features. * p < 0.05 compared to group 2. ‘n’ denotes number of patients.
Table 1. Demographic features. * p < 0.05 compared to group 2. ‘n’ denotes number of patients.
Group 1Group 2Group 3
Gender (n) M/F18/157/414/6
Age54.82 ± 5.4852.36 ± 5.0353.55 ± 2.99
Pterygium vertical length3.77 ± 0.114.5 ± 0.34.02 ± 0.21
Duration between recurrences (month)07.73±1.1681 ± 17.8 *
Recurrence number012.3 ± 0.39
Table
Table 2. Levels of SP and VIP.
Table 2. Levels of SP and VIP.
Group 1 (n= 33)Group 2 (n= 11)Group 1 vs. Group 2Group 3 (n= 20)Group 1 vs. Group 3
VIP13.59 (±2.63)57.38 (±18.31)p < 0.00135.60 (±6.4)p < 0.05
SP22.99 (±4.61)98.14 (±27.13)p < 0.00156.94 (±10.18)p < 0.05
Table
Table 3. SP and VIP values in relation to time between last two recurrences * p = 0.0134 compared to the group that recurred after 6 months. ‘n’ denotes number of patients.
Table 3. SP and VIP values in relation to time between last two recurrences * p = 0.0134 compared to the group that recurred after 6 months. ‘n’ denotes number of patients.
Recurrence after Last Surgery (n)SPVIP
0–6 months11112.53 ± 25.63 *57.37 ± 24.79
After 6 months643.39 ± 9.7541.83 ± 11.42
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

İlhan, H.D.; Ünal, B.; Ayaz, Y.; Erin, N. Changes in TRPV1 Expression as Well as Substance P and Vasoactive Intestinal Peptide Levels Are Associated with Recurrence of Pterygium. Int. J. Mol. Sci. 2022, 23, 15692. https://doi.org/10.3390/ijms232415692

AMA Style

İlhan HD, Ünal B, Ayaz Y, Erin N. Changes in TRPV1 Expression as Well as Substance P and Vasoactive Intestinal Peptide Levels Are Associated with Recurrence of Pterygium. International Journal of Molecular Sciences. 2022; 23(24):15692. https://doi.org/10.3390/ijms232415692

Chicago/Turabian Style

İlhan, Hatice Deniz, Betül Ünal, Yusuf Ayaz, and Nuray Erin. 2022. "Changes in TRPV1 Expression as Well as Substance P and Vasoactive Intestinal Peptide Levels Are Associated with Recurrence of Pterygium" International Journal of Molecular Sciences 23, no. 24: 15692. https://doi.org/10.3390/ijms232415692

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop